Presynaptic inhibition of transmitter release from rat sympathetic neurons by bradykinin.
Bradykinin is known to stimulate neurons in rat sympathetic ganglia and to enhance transmitter release from their axons by interfering with the autoinhibitory feedback, actions that involve protein kinase C. Here, bradykinin caused a transient increase in the release of previously incorporated [3H] noradrenaline from primary cultures of dissociated rat sympathetic neurons. When this effect was abolished by tetrodotoxin, bradykinin caused an inhibition of tritium overflow triggered by depolarizing K+ concentrations. This inhibition was additive to that caused by the alpha2-adrenergic agonist UK 14304, desensitized within 12 min, was insensitive to pertussis toxin, and was enhanced when protein kinase C was inactivated. The effect was half maximal at 4 nm and antagonized competitively by the B2 receptor antagonist Hoe 140. The cyclooxygenase inhibitor indomethacin and the angiotensin converting enzyme inhibitor captopril did not alter the inhibition by bradykinin. The M-type K+ channel opener retigabine attenuated the secretagogue action of bradykinin, but left its inhibitory action unaltered. In whole-cell patch-clamp recordings, bradykinin reduced voltage-activated Ca2+ currents in a pertussis toxin-insensitive manner, and this action was additive to the inhibition by UK 14304. These results demonstrate that bradykinin inhibits noradrenaline release from rat sympathetic neurons via presynaptic B2 receptors. This effect does not involve cyclooxygenase products, M-type K+ channels, or protein kinase C, but rather an inhibition of voltage-gated Ca2+ channels.
Edelbauer
Hannah
H
Institute of Pharmacology, Medical University of Vienna, Vienna, Austria.
Lechner
Stefan G
SG
Mayer
Martina
M
Scholze
Thomas
T
Boehm
Stefan
S
D000806:Angiotensin-Converting Enzyme Inhibitors / Q000494:pharmacology; D000818:Animals; D001920:Bradykinin / Q000494:pharmacology*; D015220:Calcium Channels / Q000502:physiology; D002219:Carbamates / Q000494:pharmacology; D002478:Cells, Cultured; D016861:Cyclooxygenase Inhibitors / Q000494:pharmacology; D004553:Electric Conductivity; D004558:Electric Stimulation; D004789:Enzyme Activation / Q000502:physiology; D005728:Ganglia, Sympathetic / Q000378:metabolism*; D009474:Neurons / Q000378:metabolism*; D009638:Norepinephrine / Q000037:antagonists & inhibitors*; D010655:Phenylenediamines / Q000494:pharmacology; D011188:Potassium / Q000494:pharmacology; D015221:Potassium Channels / Q000187:drug effects / Q000378:metabolism; D017729:Presynaptic Terminals / Q000378:metabolism*; D011493:Protein Kinase C / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D018341:Receptors, Adrenergic, alpha-2 / Q000378:metabolism; D015398:Signal Transduction / Q000502:physiology; D013997:Time Factors; D014316:Tritium / Q000493:pharmacokinetics
D000806:Angiotensin-Converting Enzyme Inhibitors; D015220:Calcium Channels; D002219:Carbamates; D016861:Cyclooxygenase Inhibitors; D010655:Phenylenediamines; D015221:Potassium Channels; D018341:Receptors, Adrenergic, alpha-2; D014316:Tritium; C101866:ezogabine; D011493:Protein Kinase C; D011188:Potassium; D001920:Bradykinin; D009638:Norepinephrine